rss-es – Página 183

Boston Scientific Corporation (NYSE: BSX) has announced it has initiated a global, voluntary recall of all unused inventory of the LOTUS Edge™ Aortic Valve System due to complexities associated with the product delivery system. The voluntary recall is related solely to the delivery system, as the va

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/boston-scientific-announces-lotus-edgetm-aortic-valve-system-voluntary-recall-and-product

rss rss-es rss-pt

País suma 1.447 casos COVID-19 el miércoles, 1.369 el jueves y 1.207 el viernes: 177.614 casos COVID-19 totales

Murilo Freitas - 21:03, 7 de enero de 2021468

País suma 1.447 casos COVID-19 el miércoles, 1.369 el jueves y 1.207 el viernes: 177.614 casos COVID-19 totales

Viernes 08 de enero, 2021. El país registró 1.447 casos nuevos de COVID-19 el miércoles 06 de enero, 1.369 el jueves 07 de enero y 1.207 casos el viernes 08 de enero..

https://www.ministeriodesalud.go.cr/index.php/centro-de-prensa/noticias/746-noticias-2021/2028-pais-suma-1-447-casos-covid-19-el-miercoles-1-369-el-jueves-y-1-207-el-viernes-177-614-casos-covid-19-totales

rss rss-es rss-pt

Coronavirus (COVID-19) Update: January 8, 2021

Murilo Freitas - 20:28, 7 de enero de 2021475

Coronavirus (COVID-19) Update: January 8, 2021
http://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-january-8-2021

rss rss-es rss-pt

FDA Issues Alert Regarding SARS-CoV-2 Viral Mutation to Health Care Providers and Clinical Laboratory Staff

Murilo Freitas - 16:47, 7 de enero de 2021424

FDA Issues Alert Regarding SARS-CoV-2 Viral Mutation to Health Care Providers and Clinical Laboratory Staff
http://www.fda.gov/news-events/press-announcements/fda-issues-alert-regarding-sars-cov-2-viral-mutation-health-care-providers-and-clinical-laboratory

rss rss-es rss-pt

Fresenius Kabi Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP Due to the Presence of Particulate Matter

Murilo Freitas - 05:00, 7 de enero de 2021412

Fresenius Kabi USA is voluntarily recalling a single lot of Ketorolac Tromethamine Injection, USP, 30 mg/mL, 1 mL fill in a 2 mL amber vial to the user level due to the presence of particulate matter. Particulate matter was found in reserve sample vials. No adverse event reports have been received

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/fresenius-kabi-issues-voluntary-nationwide-recall-ketorolac-tromethamine-injection-usp-due-presence

rss rss-es rss-pt